Analysts predict that West Pharmaceutical Services Inc. (NYSE:WST) will post $0.72 earnings per share (EPS) for the current fiscal quarter, Zacks Investment Research reports. Two analysts have provided estimates for West Pharmaceutical Services’ earnings. The lowest EPS estimate is $0.71 and the highest is $0.73. West Pharmaceutical Services reported earnings per share of $0.67 in the same quarter last year, which suggests a positive year-over-year growth rate of 7.5%. The business is expected to report its next quarterly earnings results on Thursday, October 25th.

According to Zacks, analysts expect that West Pharmaceutical Services will report full-year earnings of $2.82 per share for the current financial year, with EPS estimates ranging from $2.80 to $2.84. For the next fiscal year, analysts anticipate that the company will post earnings of $3.22 per share, with EPS estimates ranging from $3.06 to $3.35. Zacks Investment Research’s EPS calculations are a mean average based on a survey of research firms that follow West Pharmaceutical Services.

West Pharmaceutical Services (NYSE:WST) last announced its quarterly earnings data on Thursday, July 26th. The medical instruments supplier reported $0.70 earnings per share for the quarter, beating analysts’ consensus estimates of $0.67 by $0.03. The business had revenue of $447.50 million for the quarter, compared to analyst estimates of $422.57 million. West Pharmaceutical Services had a return on equity of 15.38% and a net margin of 8.99%. The company’s revenue was up 12.6% on a year-over-year basis. During the same period in the prior year, the company earned $0.66 earnings per share.

A number of brokerages have recently commented on WST. Zacks Investment Research upgraded West Pharmaceutical Services from a “hold” rating to a “buy” rating and set a $123.00 target price on the stock in a research note on Tuesday, July 31st. ValuEngine upgraded West Pharmaceutical Services from a “sell” rating to a “hold” rating in a research note on Tuesday, June 12th. One investment analyst has rated the stock with a sell rating, four have issued a hold rating and one has given a buy rating to the company’s stock. The stock has a consensus rating of “Hold” and an average price target of $107.00.

Shares of WST traded down $0.18 during mid-day trading on Tuesday, reaching $122.59. The company had a trading volume of 259,900 shares, compared to its average volume of 379,471. West Pharmaceutical Services has a 52-week low of $82.74 and a 52-week high of $124.51. The company has a quick ratio of 1.94, a current ratio of 2.67 and a debt-to-equity ratio of 0.15. The company has a market capitalization of $8.94 billion, a price-to-earnings ratio of 44.34, a PEG ratio of 4.13 and a beta of 1.20.

In other news, SVP Karen Flynn sold 20,458 shares of the company’s stock in a transaction dated Tuesday, August 7th. The stock was sold at an average price of $116.23, for a total value of $2,377,833.34. Following the sale, the senior vice president now owns 31,051 shares in the company, valued at $3,609,057.73. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. 2.70% of the stock is owned by corporate insiders.

Institutional investors and hedge funds have recently modified their holdings of the company. Mason Street Advisors LLC boosted its position in West Pharmaceutical Services by 1.6% during the first quarter. Mason Street Advisors LLC now owns 37,161 shares of the medical instruments supplier’s stock worth $3,281,000 after purchasing an additional 579 shares in the last quarter. Quest Investment Management LLC boosted its position in West Pharmaceutical Services by 2.2% during the first quarter. Quest Investment Management LLC now owns 28,316 shares of the medical instruments supplier’s stock worth $2,500,000 after purchasing an additional 609 shares in the last quarter. Janney Montgomery Scott LLC boosted its position in West Pharmaceutical Services by 14.1% during the second quarter. Janney Montgomery Scott LLC now owns 4,926 shares of the medical instruments supplier’s stock worth $489,000 after purchasing an additional 609 shares in the last quarter. Municipal Employees Retirement System of Michigan boosted its position in West Pharmaceutical Services by 2.7% during the first quarter. Municipal Employees Retirement System of Michigan now owns 22,990 shares of the medical instruments supplier’s stock worth $2,030,000 after purchasing an additional 610 shares in the last quarter. Finally, Whittier Trust Co. of Nevada Inc. boosted its position in West Pharmaceutical Services by 31.6% during the second quarter. Whittier Trust Co. of Nevada Inc. now owns 2,624 shares of the medical instruments supplier’s stock worth $261,000 after purchasing an additional 630 shares in the last quarter. Hedge funds and other institutional investors own 95.97% of the company’s stock.

About West Pharmaceutical Services

West Pharmaceutical Services, Inc manufactures and sells containment and delivery systems for injectable drugs and healthcare products in the United States, Germany, France, Other European countries, and internationally. The company operates through two segments, Proprietary Products and Contract-Manufactured Products.

Read More: Hedge Funds – Risk or Reward?

Get a free copy of the Zacks research report on West Pharmaceutical Services (WST)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for West Pharmaceutical Services Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for West Pharmaceutical Services and related companies with MarketBeat.com's FREE daily email newsletter.